6-K ·Filed Apr 20, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor upcoming clinical trial announcements for these candidates, as preclinical success doesn't guarantee clinical efficacy. The stock reaction will depend on future clinical data.
Final — all horizons settled through T+60d ⚠ clustered
AAPG ▼ -23.44% at T+60d
NEUTRAL call -23.44% · α vs SPY -30.22% · entry $26.36 → $20.18
T+1d
-2.69%
call -2.69% · α -2.04%
$25.65
settled 6mo ago
T+5d
-11.34%
call -11.34% · α -12.26%
$23.37
settled 6mo ago
T+20d
-29.59%
call -29.59% · α -33.79%
$18.56
settled 5mo ago
T+60d
-23.44%
call -23.44% · α -30.22%
$20.18
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Ascentage Pharma announced four preclinical studies at AACR 2026, highlighting potential new uses for its drug candidates in endometrial carcinoma, mantle cell lymphoma, BRAF-mutant tumors, and small-cell lung cancer. The data supports future clinical development of combination therapies.
Key Facts
- Presented four preclinical studies at AACR 2026 Annual Meeting
- Studies feature olverembatinib, APG-2449, and APG-5918
- Research explores new applications beyond approved uses, including combination therapies
- All drug candidates are investigational and not FDA-approved
Financial Impact
No immediate financial impact - preclinical data only
Risk Factors
- Preclinical results may not translate to human trials
- Development timelines could be delayed
- Competition in targeted cancer therapies
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-045375 |
| Document: ea028690901ex99-2.htm | 0001213900-26-045375 |
| Document: ea0286909-6k_ascentage.htm | 0001213900-26-045375 |
| Document: 0001213900-26-045375-index-headers.html | 0001213900-26-045375 |
| Document: 0001213900-26-045375-index.html | 0001213900-26-045375 |
| Document: 0001213900-26-045375.txt | 0001213900-26-045375 |
29 reports for AAPG
67% Hit rate @ T+1 Went positive at some point 5 of 6 best @ T+20▲ +13.03%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.85 (−3.82%) |
Oct 21, 2026 6d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.85 (−0.47%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.85 (+1.09%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.85 (+3.38%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.85 (+14.26%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.85 (−11.90%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.85 (−11.63%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.85 (−21.39%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.85 (−19.16%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.85 (−22.82%) |
Showing 10 of 29
US Market Status
Market Closed — Opens Wed (16h 24m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers